| Identification | Back Directory | [Name]
Glycine, L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginylglycyl-L-prolyl-L-valyl-L-lysyl-L-arginyl-L-arginyl-L-leucyl-L-phenylalanyl- | [CAS]
237392-84-6 | [Synonyms]
Glycine, L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginylglycyl-L-prolyl-L-valyl-L-lysyl-L-arginyl-L-arginyl-L-leucyl-L-phenylalanyl- | [Molecular Formula]
C111H196N48O23 | [MOL File]
237392-84-6.mol | [Molecular Weight]
2571.05 |
| Hazard Information | Back Directory | [Uses]
Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner[1]. | [References]
[1] Chen YN, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4325-9. DOI:10.1073/pnas.96.8.4325 |
|
|